Three distinct D-amino acid substitutions confer potent antiangiogenic activity on an inactive peptide derived from a thrombospondin-1 type 1 repeat

Molecular Pharmacology

Volumn 55, Issue 2, 1999, Pages 332-338

  Dawson, David W ^a   Volpert, Olga V ^a   Frieda A Pearce, S ^b   Schneider, Andrew J ^c   Silverstein, Roy L ^b   Henkin, Jack ^c   Bouck, Noël P ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

^c ABBOTT LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACIDIC FIBROBLAST GROWTH FACTOR; ANGIOGENESIS INHIBITOR; DEXTRO AMINO ACID; PLATELET DERIVED GROWTH FACTOR; THROMBOSPONDIN 1; VASCULOTROPIN;

AMINO ACID SUBSTITUTION; ANGIOGENESIS; ANIMAL TISSUE; ARTICLE; CAPILLARY ENDOTHELIUM; CORNEA ENDOTHELIUM; DRUG POTENCY; ENANTIOMER; ENDOTHELIUM CELL; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; PEPTIDE SYNTHESIS; PRIORITY JOURNAL; PROTEIN DOMAIN; RAT; VASCULAR ENDOTHELIUM;

EID: 0033027727     PISSN: 0026895X     EISSN: None     Source Type: Journal    
DOI: 10.1124/mol.55.2.332     Document Type: Article

References (39)

1. Asch AS, Silbiger S, Heimer E and Nachman RL (1992) Thrombospondin sequence motif (CSVTCG) is responsible for CD36 binding. Biochem Bicphys Res Comm 182:1208-1217.
2. Boehm T, Folkman J, Browder T and O'Reilly MS (1997) Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature (London) 390:404-407.
3. Bornstein P (1995) Diversity of function is inherent in matricellular proteins: An appraisal of thrombospondin 1. J Cell Biol 130:503-506.
4. Bouck N, Stellmach V and Hsu S (1996) How tumors become angiogenic. Adv Cancer Res 69:135-174.
5. Castle VP, Dixit VM and Polverini PJ (1997) Thrombospondin-1 suppresses tumor-igenesis and angiogenesis in serum- and anchorage-independent NIH 3T3 cells. Lab Invest 77:51-61.
6. Daviet L, Buckland R, Puente Navazo MD and McGregor JL (1995) Identification of an immunodominant functional domain on human CD36 antigen using human-mouse chimaeric proteins and homologue-replacement mutagenesis. Biochem J 305221-224.
7. Dawson DW, Pearce SFA, Zhong R, Silverstein RL, Frazier WA and Bouck NP (1997) CD36 mediates the in vitro inhibitory effects of thrombospondin-1 on endothelial cells. J Cell Biol 138:707-717.
8. DiPietro LA (1997) Thrombospondin as a regulator of angiogenesis, in Regulation of Angiogenesis (Goldberg TD and Rosen EM eds) pp 295-313, Birkhauser Verlag, Basel.
9. Fauchere J-L and Thurieau C (1992) Evaluation of the stability of peptides and pseudopeptides as a tool in peptide drug design. Adv Drug Res 23:127-159.
10. Folkman J (1995a) Clinical applications of research on angiogenesis. N Engl J Med 333:1757-1763.
11. Folkman J (1995b) Tumor angiogenesis, in The Molecular Basis of Cancer (Mendelsohn J, Howley PM, Israel MA and Liotta LA eds) pp 206-232, W.B. Saunders Company, Philadelphia.
12. Folkman J and Klagsbrun M (1987) Angiogenic factors. Science (Wash DC) 235:442-447.
13. Gately S, Twardowski P, Stack MS, Patrick M, Boggio L, Cundiff DL, Schnaper HW, Madison L, Volpert O, Bouck N, Enghild J, Kwaan HC and Soff GA (1996) Human prostate carcinoma cells express enzymatic activity that converts human plasminogen to the angiogenesis inhibitor, angiostatin. Cancer Res 56:4887-4890.
14. Good DJ, Polverini PJ, Rastinejad F, Le Beau MM, Lemons RS, Frazier WA and Bouck NP (1990) A tumor suppressor-dependent inhibitor of angiogenesis is immunologically and functionally indistinguishable from a fragment of thrombospondin. Proc Natl Acad Sci USA 87:6624-6628.
15. Gradishar W (1997) An overview of clinical trials involving inhibitors of angiogenesis and their mechanism of action. J Invest New Drugs 15:49-59.
16. Guo N, Krutzsch HC, Inman JK and Roberts DD (1997a) Thrombospondin 1 and type I repeat peptides of thrombospondin 1 specifically induce apoptosis of endothelial cells. Cancer Res 57:1735-1742.
17. Guo NH, Krutzsch HC, Inman JK, Shannon CS and Roberts DD (1997b) Antiproliferative and antitumor activities of D-reverse peptides derived from the second type-1 repeat of thrombospondin-1. J Peptide Res 50:210-221.
18. Johnson MD, Kim HR, Chesler L, Tsao-Wu G, Bouck N and Polverini PJ (1994) Inhibition of angiogenesis by tissue inhibitor of metalloproteinase. J Cell Physiol 160:194-202.
19. Kenyon BM, Voest EE, Chen CC, Flynn E, Folkman J and D'Amato RJ (1996) A model of angiogenesis in the mouse cornea. Invest Ophthalmol & Visual Sci 37:1625-1632.
20. Kieffer N, Bettaieb A, Legrand C, Coulombel L, Vainchenker W, Edelman L and Breton-Gorius J (1989) Developmentally regulated expression of a 78 kDa erythroblast membrane glycoprotein immunologically related to the platelet thrombospondin receptor. Biochem J 262:835-842.
21. Klagsbrun M and D'Amore PA (1991) Regulators of angiogenesis. Annu Rev Physiol 53:217-239.
22. Lahav J (1993) The functions of thrombospondin and its involvement in physiology and pathology. Biochim Biophys Acta 1182:1-14.
23. Li WS, Howard RJ and Leung LLK (1993) Identification of SVTCG in thrombospondin as the conformation-dependent, high affinity binding site for its receptor, CD36. J Biol Chem 268:16179-16184.
24. Lingen MW, Polverini PJ and Bouck NP (1996) Inhibition of squamous cell carcinoma angiogenesis by direct interaction of retinoic acid with endothelial cells. Lab Invest 74:476-483.
25. Morley JS (1980) Modulation of the action of regulatory peptides by structural modifications. Trends Pharmacol Sci 1:463-468.
26. Moscatelli D and Rifkin DB (1988) Membrane and matrix localization of proteinases: A common theme in tumor cell invasion and angiogenesis. Biochim Biophys Acta 948:67-85.
27. Pluda JM (1997) Tumor-associated angiogenesis: Mechanisms, clinical implications, and therapeutic strategies. Semin Oncol 24:203-218.
28. Polverini PJ, Bouck NP and Rastinejad F (1991) Assay and purification of a naturally occurring inhibitor of angiogenesis. Methods Enzymol 198:440-450.
29. Silverstein RL, Baird M, Lo SK and Yesner LM (1992) Sense and antisense cDNA transfection of CD36 (Glycoprotein IV) in melanoma cells. J Biol Chem 267:16607-16612.
30. Smith KF, Nolan KF, Reid KB and Perkins SJ (1991) Neutron and X-ray scattering studies of the human complement protein properdin provides an analysis of the human thrombospondin repeat. Biochemistry 30:8000-8008.
31. Spatola AF (1983) Peptide backbone modifications: A structure-activity analysis of peptides containing amide bond surrogates, conformational constraints, and related backbone replacements, in Chemistry and Biochemistry of Amino Acids, Peptides, and Proteins (Weinstein B ed) vol 7, pp 267-358, Marcel Dekker, New York.
32. Tolsma SS (1995) Inhibition of angiogenesis controlled by tumor 1 suppressor genes: Thrombospondin-1 and its derived peptides. Thesis, Northwestern University 265 p.
33. Tolsma SS, Stack MS and Bouck N (1997) Lumen formation and other angiogenic activities of cultured capillary endothelial cells are inhibited by thrombospondin-1. Microvasc Res 54:13-26.
34. Tolsma SS, Volpert OV, Good DJ, Frazier WA, Polverini PJ and Bouck N (1993) Peptides derived from two separate domains of the matrix protein thrombospondin-1 have anti-angiogenic activity. J Cell Biol 122:497-511.
35. Vogel T, Guo NH, Krutsch HC, Blake DA, Hartman J, Mendelovitz S, Panet A and Roberts DD (1993) Modulation of endothelial cell proliferation, adhesion, and motility by recombinant heparin-binding domain and synthetic peptides derived from the type I repeats of thrombospondin. J Cell Biochem 53:74-84.
36. Volpert OV, Dameron KM and Bouck N (1997) Sequential development of an angiogenic phenotype by human fibroblasts progressing to tumorigenicity. Oncogene 14:1495-1502.
37. Volpert OV, Tolsma SS, Pellerin S, Feige J-J, Chen H, Mosher DF and Bouck N (1995) Inhibition of angiogenesis by thrombospondin-2. Biochem Biophys Res Commun 217:326-332.
38. Volpert OV, Ward WF, Lingen MW, Chesler L, Solt DB, Johnson MD, Molteni A, Polverini PJ and Bouck NP (1996) Captopril inhibits angiogenesis and slows the growth of experimental tumors in rats. J Clin Invest 98:671-679.
39. Weinstat-Saslow DL, Zabrentzky VS, VanHoutte K, Frazier WA, Roberts DD and Steeg PS (1994) Transfection of thrombospondin 1 complementary DNA into a human breast carcinoma cell line reduces primary tumor growth, metastatic potential, and angiogenesis. Cancer Res 54:6504-6511.